Matthew H. Taylor, MD, discusses the preliminary data on the use of IO-108 in advanced solid tumors in a phase 1 study.
Matthew H. Taylor, MD, Oregon Health
Advertisement
Articles by Matthew H. Taylor, MD, Oregon Health
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
CELMoDs and Bispecifics Break Through Across Lymphomas and Leukemias at EHA 2026
2
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
3
Aglatimagene Besadenovec Plus EBRT Improves Prostate Cancer-Specific DFS
4
Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026
5